BioLife Solutions (NASDAQ:BLFS) Major Shareholder Sells $5,925,000.00 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) major shareholder Casdin Partners Master Fund, L sold 250,000 shares of BioLife Solutions stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $23.70, for a total transaction of $5,925,000.00. Following the completion of the transaction, the insider owned 5,407,165 shares in the company, valued at approximately $128,149,810.50. This represents a 4.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Thursday, May 21st, Casdin Partners Master Fund, L sold 650,000 shares of BioLife Solutions stock. The shares were sold at an average price of $23.70, for a total transaction of $15,405,000.00.
• On Tuesday, May 19th, Casdin Partners Master Fund, L sold 300,000 shares of BioLife Solutions stock. The shares were sold at an average price of $22.65, for a total transaction of $6,795,000.00.

BioLife Solutions Stock Performance

NASDAQ BLFS traded up $0.74 during trading on Thursday, reaching $24.74. The company’s stock had a trading volume of 1,074,792 shares, compared to its average volume of 468,051. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -309.21 and a beta of 1.97. BioLife Solutions, Inc. has a twelve month low of $17.86 and a twelve month high of $29.62. The business’s fifty day moving average price is $20.58 and its 200-day moving average price is $22.94.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The company had revenue of $27.50 million for the quarter, compared to analyst estimates of $25.66 million. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. As a group, sell-side analysts forecast that BioLife Solutions, Inc. will post 0.09 EPS for the current fiscal year.

Institutional Investors Weigh In On BioLife Solutions

A number of hedge funds and other institutional investors have recently bought and sold shares of BLFS. Global Retirement Partners LLC acquired a new stake in BioLife Solutions in the fourth quarter valued at $30,000. Kemnay Advisory Services Inc. acquired a new position in shares of BioLife Solutions during the 4th quarter worth $35,000. Hantz Financial Services Inc. grew its stake in shares of BioLife Solutions by 54.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 659 shares during the period. Quarry LP grew its stake in shares of BioLife Solutions by 50.9% during the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 713 shares during the period. Finally, State of Wyoming acquired a new position in BioLife Solutions during the first quarter worth about $52,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Monday, April 20th. Wall Street Zen upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Zacks Research lowered shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 12th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, BioLife Solutions has an average rating of “Hold” and a consensus target price of $32.00.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.